Senseonics Holdings

Senseonics Holdings, Inc. engages in the design, development, and commercialization of an implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a glucose monitoring device which includes sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Senseonics achieves FDA milestone with Eversense 365, focuses on growth

Senseonics had a pivotal quarter with FDA approval of Eversense 365, driving positive feedback and strong adoption.
Financially, the company reported Q3 net revenue of $4.3 million with a gross loss of $4.1 million, focusing on cost reduction.
Efforts to reduce operating expenses and extend cash runway aim to address financial challenges and enhance stability.
With opportunities to accelerate sales, improve diabetes management, and expand market reach, Senseonics is poised for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics has had a large win via the Ascensia Diabetes collaboration structure, that creates shareholder value with long-tailed returns. The Eversense device will benefit from Ascensia's large footprint in Medicare, and allow them to do the heavy lifting on Senseonic's behalf.

Senseonics Holdings Is A Winner With The Ascensia Deal In Glucose Monitoring

Senseonics Holdings, Inc. (SENS) CEO Tim Goodnow on Q3 2020 Results - Earnings Call Transcript

Senseonics (SENS) delivered earnings and revenue surprises of -66.67% and -2.42%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Senseonics Holdings (SENS) Reports Q3 Loss, Lags Revenue Estimates

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended September 30, 2020. Recent Highlights & Accomplishments: Reinitiated Eversense® new patient sales and marketing activities in the U.S. with Ascensia Diabetes Care on October 1, 2020 S

Senseonics Holdings, Inc. Reports Third Quarter 2020 Financial Results

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced entrance into an equity line of credit financing agreement with current shareholder Energy Capital, LLC for up to $12.0 million. “This line of credit provides the opportunity to increase liquidity as needed in 2021 or 2022 for

Senseonics Announces Equity Line of Credit Financing Agreement

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the company plans to participate in the upcoming Credit Suisse virtual Healthcare Conference. Management is scheduled to present Wednesday, November 11, 2020 at 10:15 am ET. Interested parties may access a live and recorded we

Senseonics to Participate in the Credit Suisse Healthcare Conference

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2020 financial results after market close on Monday, November 9, 2020. Management will hold a conference call to review the company's third quarter 2020 performance starting at 4:30 p

Senseonics Holdings, Inc. Schedules Third Quarter 2020 Earnings Release and Conference Call for November 9, 2020 at 4:30 p.m. Eastern Time

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the Premarket Approval (PMA) supplement application to extend the wearable life of the Eversense® CGM System to 180 days was submitted to the United States Food and Drug Administration (FDA) on September 30. Summary accuracy r

Senseonics Submits PMA Application for 180-Day Eversense System to the FDA

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc.

Senseonics Announces Analyst and Investor Event on September 15, 2020

Senseonics Holdings, Inc. (SENS) CEO Tim Goodnow on Q2 2020 Results - Earnings Call Transcript

Senseonics (SENS) delivered earnings and revenue surprises of 100.00% and -76.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Senseonics Holdings (SENS) Reports Break-Even Earnings for Q2

Senseonics Holdings, Inc. Reports Second Quarter 2020 Financial Results

Senseonics Announces Strategic Collaboration with Ascensia Diabetes Care

TOKYO and BASEL, Switzerland, Aug. 10, 2020 /PRNewswire/ -- PHC Holdings Corporation and Ascensia Diabetes Care, a PHC Group company, today announced a strategic partnership with Senseonics Holdings, Inc.

PHC Holdings Corporation and Ascensia Diabetes Care Announce Financing Agreement and Exclusive Global Commercial Agreement With Senseonics

Senseonics Announces Positive Coverage Decision for Eversense CGM from Highmark Inc.

Senseonics Holdings, Inc. Schedules Second Quarter 2020 Earnings Release and Conference Call for August 10, 2020 at 4:30 p.m.

NEW YORK, Aug. 3, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Senseonics Holdings, Inc.

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Senseonics Holdings, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

Senseonics (SENS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Senseonics Holdings (SENS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Senseonics Holdings (SENS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Senseonics Holdings (SENS) Catches Eye: Stock Jumps 5.7%

Senseonics Holdings, Inc. (SENS) CEO Tim Goodnow on Q1 2020 Results - Earnings Call Transcript

Senseonics (SENS) delivered earnings and revenue surprises of -75.00% and -95.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Senseonics Holdings (SENS) Reports Q1 Loss, Misses Revenue Estimates

Senseonics Holdings (SENS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Senseonics Holdings, Inc. (SENS) CEO Tim Goodnow on Q4 2019 Results - Earnings Call Transcript

Exact Sciences

HealthEquity

An overall market sell-off stemming from increased coronavirus worries weighed on all three healthcare stocks.

News for Senseonics Holdings Stock (SENS)